Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs

Inclusion Criteria: * HIV-infected adults (≥18 years of age) with a history of IDU as the principal HIV transmission risk factor or with current or recent (past 12 months) history of IDU * Either currently receiving an antiretroviral regimen but experiencing adherence or tolerability issues on current ART or restarting ART after an unscheduled treatment interruption * Willing to switch current ART regimen * No documented viral resistance to currently licensed HIV-1 integrase inhibitors, abacavir and lamivudine based either on previous HIV-1 genotypic resistance testing or in the judgment of the study investigators * Integrase inhibitor naïve (defined as no-prior exposure to any INSTI) * Documented negative HLAB\*5701 allele Exclusion Criteria: * Subjects with active hepatitis B infection (defined as hepatitis B surface antigen (sAg) positive) * Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification; * Chronic renal failure estimated by glomerular filtration rate (eGFR) \<60mls/min/1.73m2 at screening using the abbreviated Modification of Diet in Renal Disease (MDRD) equation * Any active illness (including AIDS-defining illness) which in the opinion of the investigator would prevent the subject from completing all study assessments * Female subjects who are pregnant, breastfeeding or planning future pregnancies or unwilling to take measures to avoid pregnancy for the study duration * Any grade 4 laboratory abnorm…